MA54673B2 - Stéroïdes et leurs conjugués-anticorps - Google Patents

Stéroïdes et leurs conjugués-anticorps

Info

Publication number
MA54673B2
MA54673B2 MA54673A MA54673A MA54673B2 MA 54673 B2 MA54673 B2 MA 54673B2 MA 54673 A MA54673 A MA 54673A MA 54673 A MA54673 A MA 54673A MA 54673 B2 MA54673 B2 MA 54673B2
Authority
MA
Morocco
Prior art keywords
steroids
antibody conjugates
glucocorticoids
steroid
cells
Prior art date
Application number
MA54673A
Other languages
English (en)
French (fr)
Other versions
MA54673A1 (fr
Inventor
Amy Han
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of MA54673A1 publication Critical patent/MA54673A1/fr
Publication of MA54673B2 publication Critical patent/MA54673B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA54673A 2018-01-08 2019-01-08 Stéroïdes et leurs conjugués-anticorps MA54673B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862614905P 2018-01-08 2018-01-08
PCT/US2019/012786 WO2019136487A2 (en) 2018-01-08 2019-01-08 Steroids and antibody-conjugates thereof

Publications (2)

Publication Number Publication Date
MA54673A1 MA54673A1 (fr) 2022-08-31
MA54673B2 true MA54673B2 (fr) 2025-10-31

Family

ID=65411936

Family Applications (2)

Application Number Title Priority Date Filing Date
MA54673A MA54673B2 (fr) 2018-01-08 2019-01-08 Stéroïdes et leurs conjugués-anticorps
MA50259A MA50259A1 (fr) 2018-01-08 2019-01-08 Stéroïdes et leurs conjugués-anticorps

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA50259A MA50259A1 (fr) 2018-01-08 2019-01-08 Stéroïdes et leurs conjugués-anticorps

Country Status (19)

Country Link
US (3) US12070506B2 (https=)
EP (1) EP3737420A2 (https=)
JP (2) JP7366028B2 (https=)
KR (1) KR102786381B1 (https=)
CN (2) CN118955604A (https=)
AU (1) AU2019205542B2 (https=)
BR (1) BR112020013492A2 (https=)
CA (1) CA3086926A1 (https=)
CL (1) CL2020001813A1 (https=)
CO (1) CO2020009644A2 (https=)
EA (1) EA202091672A1 (https=)
IL (2) IL319417A (https=)
MA (2) MA54673B2 (https=)
MX (1) MX2020006994A (https=)
MY (1) MY210236A (https=)
PH (1) PH12020551044A1 (https=)
SG (1) SG11202006510XA (https=)
WO (1) WO2019136487A2 (https=)
ZA (1) ZA202003956B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3046537T3 (en) 2016-11-08 2025-12-02 Regeneron Pharma Steroids and protein-conjugates thereof
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
SG11202006510XA (en) 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
CN118955710A (zh) 2018-05-09 2024-11-15 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
BR112021013464A2 (pt) * 2019-01-08 2021-09-21 Regeneron Pharmaceuticals, Inc. Ligantes sem traço e conjugados de proteína dos mesmos
US20230119539A1 (en) * 2019-01-08 2023-04-20 Regeneron Pharmaceuticals, Inc. Traceless linkers and protein-conjugates thereof
FR3107648B1 (fr) * 2020-02-27 2022-03-18 Mc Saf conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
IT202000006442A1 (it) * 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same
JP2023072104A (ja) * 2020-04-10 2023-05-24 小野薬品工業株式会社 抗体薬物複合体
US20230355773A1 (en) * 2020-08-10 2023-11-09 P.I.F. Entrepreneurs Ltd. Macrophage targeting drug conjugates
US20220143194A1 (en) 2020-11-10 2022-05-12 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates
WO2022135332A1 (zh) * 2020-12-21 2022-06-30 映恩生物制药（苏州）有限公司 一种甾体偶联物
CA3207416A1 (en) * 2021-02-04 2022-08-11 Lingjian ZHU Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine
WO2022171101A1 (zh) * 2021-02-10 2022-08-18 映恩生物制药（苏州）有限公司 一种甾体偶联物
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
NL2029599B1 (en) * 2021-11-02 2023-06-01 Univ Leiden Glycosylated Prodrugs
MX2024009080A (es) 2022-01-29 2024-07-30 Shanghai Shengdi Pharmaceutical Co Ltd Conjugado farmacologico de glucocorticoide.
CA3245598A1 (en) 2022-03-11 2023-09-14 Firefly Bio, Inc. PHENYL MALEIMIDE BASED BINDER
CN115785188B (zh) * 2022-12-20 2024-06-07 湖南科益新生物医药有限公司 一种布地奈德的制备方法
CN121568722A (zh) 2023-07-28 2026-02-24 江苏恒瑞医药股份有限公司 一种含有糖皮质激素的抗体药物偶联物的药物组合物
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022898A1 (de) * 1993-04-07 1994-10-13 Schering Aktiengesellschaft Neue glucocorticoide

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2920999A (en) 1957-06-07 1960-01-12 Pfizer & Co C 21-nitrogen derivatives of corticosteroids
GB889766A (en) * 1958-03-04 1962-02-21 Olin Mathieson Improvements in steroids and the synthesis thereof
DE1165595B (de) * 1958-03-04 1964-03-19 Olin Mathieson Verfahren zur Herstellung von Triamcinolonacetonid-21-hemisuccinat und dessen Salzen
US3197469A (en) 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3007923A (en) 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
GB898291A (en) 1959-03-18 1962-06-06 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US3033874A (en) 1960-05-11 1962-05-08 Pfizer & Co C 17beta-propenoyl steroids and process for preparing same
US3033873A (en) 1960-05-11 1962-05-08 Pfizer & Co C 21-aminomethyl-pregnenes
US3020275A (en) 1960-06-07 1962-02-06 American Cyanamid Co 21-nitrogen substituted steroids of the pregnane series and methods of preparing the same
DE1169444B (de) 1961-02-22 1964-05-06 Schering Ag Verfahren zur Herstellung von ?-16ª‡-Methylsteroiden
US3047468A (en) 1961-06-06 1962-07-31 American Cyanamid Co Method of preparing delta1, 4-3-keto steroids of the pregnane series
US3383394A (en) 1965-08-30 1968-05-14 Schering Corp Novel 17-acylating process and products thereof
NL7001308A (https=) * 1969-03-07 1970-09-09
US3798216A (en) 1969-03-07 1974-03-19 Fabrication Des Antibiotique S 9-fluoro-11beta,21-dihydroxy-16alpha,17-(2-propenylidenedioxy)-pregna-1,4-diene-3,20-dione and derivatives thereof
DE2047105C3 (de) 1970-09-18 1979-02-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen 17-Chlorsteroide und Verfahren zu ihrer Herstellung
IT1057859B (it) 1972-04-28 1982-03-30 Sigma Tao Ind Farmaceutiche Sp Perivato del triamoinolone
SE378109B (https=) 1972-05-19 1975-08-18 Bofors Ab
SE378110B (https=) 1972-05-19 1975-08-18 Bofors Ab
US4076737A (en) 1975-02-20 1978-02-28 Ciba-Geigy Corporation Aldehydes of the pregnane series and derivatives thereof
IL73337A (en) 1984-10-28 1988-09-30 Yissum Res Dev Co Antitumor steroid-platinum complexes and method for the preparation thereof
SE8604059D0 (sv) 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5116829A (en) 1990-04-23 1992-05-26 Kao Corporation Steroid compounds
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
NZ259596A (en) * 1993-01-08 1997-04-24 Astra Ab Sugar-substituted glucocorticosteroid and use in medicaments specific to the colon or ileum
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5837698A (en) 1996-05-02 1998-11-17 G. D. Searle & Co. Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
WO2000049993A2 (en) 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
SE0101220D0 (sv) 2001-04-04 2001-04-04 Astrazeneca Ab New use
US6908934B2 (en) 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
ITMI20020148A1 (it) 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
GR1004274B (el) * 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
EP1562627A4 (en) * 2002-08-23 2006-11-02 Mclean Hospital Corp CORTICOSTEROID CONJUGATES AND ITS USES
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
CN1414008A (zh) 2002-10-17 2003-04-30 南开大学 含氮甾体化合物及其制备方法
US7015349B2 (en) 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005063777A1 (en) 2003-12-23 2005-07-14 Corus Pharma Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
US8101714B2 (en) 2004-02-18 2012-01-24 The University Of Georgia Research Foundation, Inc. Teleost derived antimicrobial polypeptides
US20050192257A1 (en) 2004-02-26 2005-09-01 Peyman Gholam A. Predictors for patients at risk for glaucoma from steroid therapy
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
EP1602931A1 (en) 2004-06-03 2005-12-07 Universiteit Leiden SR-A antagonists
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
DE602004017164D1 (de) 2004-08-09 2008-11-27 Deutsches Krebsforsch Albuminkonjugate, die eine Glucuron-Verknüpfung enthalten
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
WO2006135371A1 (en) 2005-06-09 2006-12-21 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
WO2006138212A1 (en) 2005-06-14 2006-12-28 Gilead Sciences, Inc. SUBSTITUTED PHENYLPHOSPHATES AS MUTUAL PRODRUGS OF STEROIDS AND β -AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US8354508B2 (en) 2006-07-21 2013-01-15 Diadexus, Inc. PRO115 antibody compositions and methods of use
JP2010503708A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド 多官能性リンカーを含む標的化ポリマープロドラッグ
EP2109617A1 (en) 2007-02-05 2009-10-21 Nicox S.A. Nitric oxide releasing steroids
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
WO2009001364A2 (en) 2007-06-28 2008-12-31 Capsutech Ltd Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
CN101397328A (zh) * 2007-09-27 2009-04-01 天津药业研究院有限公司 一氧化氮供体型糖皮质激素
PL2214646T3 (pl) * 2007-10-05 2021-12-20 Wayne State University Dendrymery do przedłużonego uwalniania związków
EP2235035A2 (en) 2007-12-21 2010-10-06 Schering Corporation C-21 thioethers as glucocorticoid receptor agonists
WO2009085879A2 (en) 2007-12-21 2009-07-09 Schering Corporation C20-c21 substituted glucocorticoid receptor agonists
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
TW201010707A (en) 2008-06-10 2010-03-16 Gilead Sciences Inc Corticosteroid linked beta-agonist compounds for use in therapy
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
WO2010010119A1 (en) 2008-07-22 2010-01-28 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
WO2010104187A1 (ja) 2009-03-09 2010-09-16 三笠製薬株式会社 ステロイド化合物
WO2010126953A1 (en) 2009-04-29 2010-11-04 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
WO2010132743A1 (en) * 2009-05-15 2010-11-18 Gilead Sciences, Inc. Corticosteroid beta-agonist compounds for use in therapy
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2536432B1 (en) 2010-02-19 2018-08-08 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
CA2806258A1 (en) 2010-07-23 2012-01-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and application thereof
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
RS53519B1 (sr) 2010-09-01 2015-02-27 Bayer Intellectual Property Gmbh N-(tetrazol-5-il)- i n-(triazol-5-il)aril amidi karboksilne kiseline i njihova upotreba kao herbicida
EA201390575A1 (ru) 2010-10-29 2014-01-30 Иммьюноджен, Инк. Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
WO2012145632A1 (en) 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
BR112014009070B1 (pt) 2011-10-14 2021-11-23 Medimmune Limited Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
US9562015B2 (en) * 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
US20130196906A1 (en) * 2012-01-31 2013-08-01 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
CN104619350A (zh) 2012-06-14 2015-05-13 Ambrx公司 结合到核受体配体多肽的抗psma抗体
MY186106A (en) 2012-10-11 2021-06-22 Ascendis Pharma As Diagnosis, prevention and treatment of diseases of the joint
BR112015008365A2 (pt) 2012-10-16 2017-07-04 Endocyte Inc composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
US9376420B2 (en) 2012-10-25 2016-06-28 Yuhan Corporation 4,5-dihydro-1H-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same
CN103044523B (zh) * 2012-12-13 2014-05-21 济南向惠医药技术有限公司 地塞米松-rgd多肽缀合物，其制备方法及应用
CA2896058A1 (en) 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
AU2014248640B2 (en) 2013-03-13 2018-03-01 Seagen Inc. Cyclodextrin and antibody-drug conjugate formulations
EP2988786A4 (en) 2013-04-22 2016-12-21 Avelas Biosciences Inc COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
WO2014197854A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
CN105517577A (zh) * 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
US20160158369A1 (en) 2013-07-10 2016-06-09 Seikagaku Corporation Pharmaceutical composition for respiratory administration
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
CN103694375B (zh) 2013-12-13 2016-10-05 北京大学 一种三萜-环糊精共价化合物及其制备方法和用途
WO2015110609A1 (en) 2014-01-24 2015-07-30 Centre National De La Recherche Scientifique Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating e. coli induced inflammatory bowel diseases such as crohn's disease
AR099812A1 (es) * 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
US10550190B2 (en) 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
WO2015189478A1 (en) 2014-06-13 2015-12-17 Glykos Finland Oy Payload-polymer-protein conjugates
HK1243931A1 (zh) 2014-12-03 2018-07-27 F. Hoffmann-La Roche Ag 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
RU2017118792A (ru) 2014-12-03 2019-01-09 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
CN107207553A (zh) 2014-12-09 2017-09-26 艾伯维公司 Bcl‑xl抑制性化合物和包括其的抗体药物缀合物
CN111620861A (zh) 2014-12-09 2020-09-04 艾伯维公司 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物
EP3250211B1 (en) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
US20170224835A1 (en) 2015-02-06 2017-08-10 Sorrento Therapeutics, Inc. Antibody Drug Conjugates
WO2016168769A1 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Chimeric receptor t cell switches for her2
IL296285A (en) 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2017006279A1 (en) 2015-07-08 2017-01-12 Aten Porus Lifesciences Cyclodextrin-polymer complexes and compostions and methods of making and using the same
WO2017044983A1 (en) 2015-09-10 2017-03-16 Shasqi, Inc. Bioorthogonal compositions
US11510993B2 (en) * 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
US10869929B2 (en) 2016-01-29 2020-12-22 Merck Sharp & Dohme Corp. Phosphonate linkers and their use to facilitate cellular retention of compounds
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
US11040108B2 (en) * 2016-04-29 2021-06-22 Brandeis University Amino acid- and peptide-steroid conjugates and use thereof
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
US20180126000A1 (en) 2016-06-02 2018-05-10 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
ES3046537T3 (en) * 2016-11-08 2025-12-02 Regeneron Pharma Steroids and protein-conjugates thereof
WO2018213082A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
WO2018218004A1 (en) * 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
WO2019034176A1 (zh) 2017-08-18 2019-02-21 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
WO2019034177A1 (zh) 2017-08-18 2019-02-21 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
SG11202006510XA (en) * 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
CN118955710A (zh) 2018-05-09 2024-11-15 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
PH12021551476A1 (en) 2018-12-21 2022-04-25 Regeneron Pharma Rifamycin analogs and antibody-drug conjugates thereof
US20230119539A1 (en) * 2019-01-08 2023-04-20 Regeneron Pharmaceuticals, Inc. Traceless linkers and protein-conjugates thereof
BR112021013464A2 (pt) 2019-01-08 2021-09-21 Regeneron Pharmaceuticals, Inc. Ligantes sem traço e conjugados de proteína dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022898A1 (de) * 1993-04-07 1994-10-13 Schering Aktiengesellschaft Neue glucocorticoide

Also Published As

Publication number Publication date
WO2019136487A3 (en) 2019-09-12
JP2024009905A (ja) 2024-01-23
EP3737420A2 (en) 2020-11-18
CN118955604A (zh) 2024-11-15
CL2020001813A1 (es) 2020-10-23
US20240342299A1 (en) 2024-10-17
IL275757B1 (en) 2025-04-01
EA202091672A1 (ru) 2021-02-01
CN112004557B (zh) 2024-07-30
US20250064954A1 (en) 2025-02-27
JP7366028B2 (ja) 2023-10-20
ZA202003956B (en) 2025-12-17
IL275757B2 (en) 2025-08-01
BR112020013492A2 (pt) 2020-12-08
CO2020009644A2 (es) 2020-10-30
CA3086926A1 (en) 2019-07-11
SG11202006510XA (en) 2020-08-28
MA50259A1 (fr) 2021-07-29
CN112004557A (zh) 2020-11-27
JP2021509908A (ja) 2021-04-08
MY210236A (en) 2025-09-04
MA54673A1 (fr) 2022-08-31
KR102786381B1 (ko) 2025-03-26
WO2019136487A2 (en) 2019-07-11
IL275757A (en) 2020-08-31
AU2019205542A1 (en) 2020-07-16
MX2020006994A (es) 2020-11-06
US12070506B2 (en) 2024-08-27
AU2019205542B2 (en) 2025-10-23
US20190209702A1 (en) 2019-07-11
IL319417A (en) 2025-05-01
PH12020551044A1 (en) 2021-04-26
KR20200108002A (ko) 2020-09-16

Similar Documents

Publication Publication Date Title
MA54673B2 (fr) Stéroïdes et leurs conjugués-anticorps
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
PH12019500365A1 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
CL2019001740A1 (es) Novedoso conjugado de amanitina.
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
BR112021016056A2 (pt) Anticorpos de claudina 6 e usos dos mesmos
JOP20200157B1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MA53069A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
MX2022012991A (es) Anticuerpos anti-vista humanos y uso de estos.
MA47392B1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA43773B1 (fr) Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
MX2021000790A (es) Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
WO2018194496A3 (ru) Моноклональное антитело к pd-l1
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
MA53186B2 (fr) Anticorps monoclonal qui se lie spécifiquement à cd20
EA202190217A1 (ru) Формы ивосидениба и фармацевтические композиции
MA45752A1 (fr) Stéroïdes et leurs conjugués protéiques
JOP20210339A1 (ar) أجسام مضادة لـ angpt2
EP4524563A3 (en) Flow based assays for therapeutics
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation